



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 08, 2009

Mylan Laboratories

[View the current Mylan Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7312-Mylan+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/7312-Mylan+Laboratories.html>)

Contact Details:

1500 Corporate Drive Suite 400

Canonsburg

PA

15317

United States of America

Tel: 724-514-1800

Fax:

Email: investor_relations@mylan.com

Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products. We focus on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and we enjoy a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products. Mylan operates three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. (all wholly-owned), and has a 71.5% controlling interest in Matrix Laboratories Limited (71.5% owned). Mylan Pharmaceuticals Inc., with locations in Morgantown, W.Va., Caguas, Puerto Rico, and Greensboro, N.C., is a world leader in the research, development, production and marketing of generic pharmaceuticals. Mylan Technologies Inc., located in St. Albans and Swanton, Vt., is a leader in transdermal drug delivery technology and is the largest producer of generic and branded transdermal patches for the U.S. market. UDL Laboratories Inc., with locations in Rockford, Ill., and Sugar Land, Texas, is the top U.S.-supplier of unit dose pharmaceuticals to hospitals and other institutions. Mylan also owns a controlling interest in India-based Matrix Laboratories Limited, which provides Mylan with a platform for global expansion and growth. Matrix is the second largest supplier of active pharmaceutical ingredient (API) sourcing and provides expanded marketing capabilities through Docpharma, a Matrix subsidiary that is a primary marketer of branded generics in Europe. Matrix is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India and currently owns, in whole or in part, 12 other facilities and business units located in India, China and South Africa.

Press Releases on Mylan Laboratories:

Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution	6th November, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution	6th November, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US
Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant	6th November, 2009	Boston Scientific Corporation	Q3 2009 Results -----
DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results	6th November, 2009	DUSA Pharmaceuticals, Inc.	-- Non-GAAP loss for the third quarter of 2009 improved 86% year over year, and narrowed to \$0.2 million. Management Comments: "We are excited to report the improvement in many
Novoxel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)	6th November, 2009		PARIS, November 6 /PRNewswire/ -- Novoxel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of

BioNews Results for Mylan Laboratories



- [Mylan Laboratories Raises Guidance](#)
Individual.com: Oct 30 2009 3:29AM Matching: mylan laboratories
- [Four Pharmaceutical Companies Pay \\$124 Million for Submission of False Claims to Medicaid](#)
Pharmacy Choice: Oct 30 2009 5:26AM Matching: mylan laboratories
- [Mylan Swings To 3Q Loss On Medicaid Settlement; Views Beat](#)
Morningstar.com: Oct 29 2009 12:03PM Matching: mylan laboratories

- [Mylan Swings To 3Q Loss On Medicaid Settlement; Views Beat](#)
Nasdaq: Oct 29 2009 11:37AM Matching: mylan laboratories
- [UPDATE: Mylan Swings To 3Q Loss On Charges; Upgrades 2009 EPS View](#)
Morningstar.com: Oct 29 2009 5:09PM Matching: mylan laboratories
- [UPDATE: Mylan Swings To 3Q Loss On Charges; Upgrades 2009 EPS View](#)
Nasdaq: Oct 29 2009 2:10PM Matching: mylan laboratories
- [2nd UPDATE: Mylan Swings To 3Q Loss On Charges; Upgrades 2009 View](#)
Morningstar.com: Oct 29 2009 6:25PM Matching: mylan laboratories
- [2nd UPDATE: Mylan Swings To 3Q Loss On Charges; Upgrades 2009 View](#)
Nasdaq: Oct 29 2009 6:13PM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
Drugs.com: Oct 29 2009 7:06PM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
PR Newswire via Yahoo!: Oct 29 2009 10:39AM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32 Mylan Raises 2009 Adjusted Diluted EPS Guidance Range to \\$1.24 - \\$1.28Solid Ope](#)
Yahoo! Canada: Oct 29 2009 11:58AM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
Pharma Live: Oct 29 2009 4:10PM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
Street Insider: Oct 29 2009 11:26AM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
Yahoo! Canada: Oct 29 2009 10:58AM Matching: mylan laboratories
- [Mylan Reports Third Quarter Adjusted Diluted EPS of \\$0.32](#)
PR Newswire via MSN Money: Oct 29 2009 10:45AM Matching: mylan laboratories

Mylan Laboratories Clinical Trials:



- [A Phase II/III Study of Cysteamine \(Mercaptoethylamine\) and Zidovudine for the Treatment of HIV Disease](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

